Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy (A-SMART)

J.M. Bryant, MD,a,* Russell F. Palm, MD,a Casey Liveringhouse, MD,a Emanuel Boyer, BS,b Pam Hodul, MD,c Mokenge Malafa, MD,c Jason Denbo, MD,c Dae Kim, MD,c Estrella Carballido, MD,c Jason B. Fleming, MD,c Sarah Hoffe, MD,a and Jessica Frakes, MDa

aDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida; bMorsani College of Medicine at the University of South Florida, Tampa, Florida; and cDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

Abstract

Purpose: Preoperative radiation therapy (RT) for pancreatic adenocarcinoma reduces positive surgical margin rates, and when delivered to an ablative dose range it may improve local control and overall survival for patients with unresectable disease. Use of stereotactic body RT to achieve a higher biologically effective dose has been limited by toxicity to adjacent radiosensitive structures, but this can be mitigated by stereotactic magnetic resonance image guided adaptive radiation therapy (SMART).

Methods and Materials: We describe our single-institution experience of high biologically effective dose SMART before resection of localized pancreatic adenocarcinoma. Toxicity was evaluated according to Common Terminology Criteria for Adverse Events (V 5.0). Tumor response was evaluated according to the College of American Pathologists tumor regression grading criteria.

Results: We analyzed 26 patients with borderline resectable (80.8%), locally advanced (11.5%), and resectable (7.7%) tumors who received ablative dose SMART (A-SMART) followed by surgical resection. Median age at diagnosis was 68 years (range, 34-86). Most patients received chemotherapy (80.8%) before RT. All patients received A-SMART to a median dose of 50 (range, 40-50) Gy in 5 fractions. Toxicity data were collected prospectively and there were no acute grade 2+ toxicities associated with RT. The median time to resection was 50 days (range, 37-115), and the procedure types included Whipple (69%), distal (23%), or total pancreatectomy (8%). The R0 resection rate was 96% and no perioperative deaths occurred within 90 days. Pathologic response was observed in 88% of cases. The time from RT to surgery was associated with tumor regression grade (P = .0003). The median follow-up after RT was 16.5 months (range, 3.9-26.2). The derived median progression-free survival from RT was 13.2 months.

Sources of support: The fees for submission of this work have been supported by an educational grant from ViewRay, the company that manufactures the MRI LINAC at our center.
Disclosures: none.

*Corresponding author: J.M. Bryant, MD; E-mail: john.bryant@moffitt.org
**Introduction**

Pancreatic adenocarcinoma (PA) is one of the most common and deadliest cancers worldwide, with an estimated 10-year overall survival (OS) of 10%.1 PA is the third leading cause of cancer-related death in the United States2 and fourth leading cause of cancer-related death in Europe.3 Historically, prolonged survival has only been achievable with surgical resection.4

Standard of care for resectable PA is surgical resection followed by adjuvant chemotherapy.5,6 Adjuvant chemotherapy regimen of Leucovorin Calcium (Folinic Acid), Fluouracil, Irinotecan Hydrochloride, and Oxaliplatin (FOLFIRINOX) is given to patients without evidence of progression after surgical resection because of improvements in survival.7 For borderline resectable (BR) cancer, the National Comprehensive Cancer Network (NCCN) guidelines recommend neoadjuvant therapy as part of a study or at high volume centers because of paucity of evidence.8 However, only 15% of patients with BR PA are able to undergo surgery.9 These patients are at risk of a 40% to 80% positive margin rate without neoadjuvant therapy.10 Approximately half of these patients will develop a local recurrence after a surgery-first approach.11,12 Although recent evidence using neoadjuvant chemoradiation demonstrates reduced positive surgical margin rates,13-15 increased pathologic tumor response,16 and improved survival17,18 the role of stereotactic body radiation therapy (SBRT) in the setting of BR disease remains controversial, as a recent phase II Alliance trial terminated the hypofractionated RT arm early because of failure of meeting the prespecified endpoint of margin negative resection.19

Evidence from inoperable patients suggests that escalation of the biologically effective dose calculated with an α/β ratio of 10 (BED10) offers improved local control (LC) that may in turn lead to an OS benefit.20-24 The use of SBRT to achieve a higher BED10 (>70 Gy22) has historically been limited by toxicity to adjacent radiosensitive structures. However, these toxicities can be mitigated by the employment of magnetic resonance-guided RT (MRgRT).22,25,26 Modern MRgRT is typically delivered with a system combining a magnetic resonance imaging (MRI) device with a traditional linear accelerator (MRL). This combination allows for improved soft-tissue visualization, real-time tracking of tumor and organs at risk (OAR) during treatment, beam gating based upon tumor position, and daily on-table adaptive replanning.27,28 These advantages increase the therapeutic window and allow for stereotactic MR-guided adaptive RT (SMART).

Preoperative SBRT has been explored in unresectable PA and has been associated with high margin negative resection rates.29-32 However, preoperative SBRT and dose escalation remain contentious due to concerns of greater surgical complication rates secondary to increased tissue density and fibrosis. To the best of our knowledge, we describe the first clinical experience of ablative dose SMART (A-SMART) before potentially curative resection of localized PA.

**Methods and Materials**

We performed a single-institution retrospective analysis with institutional review board approval of all patients with localized PA who received A-SMART, defined as BED10 ≥ 70 Gy, on the ViewRay MRIdian system (Oakwood Village, OH), followed by surgical resection with curative intent between April 2019 and May 2021. Staging and assessment of tumor resectability were performed according to NCCN guidelines, and all patients were discussed at multidisciplinary pancreatic tumor board before therapy. Patients treated with or without neoadjuvant chemotherapy were included for analysis. Gross tumor volume (GTV) was defined as primary tumor as well as any regional lymph nodes involved. SBRT has been integrated into our consensus treatment pathway at our institution for the last 15 years. We adopted higher BED10 dosing for PA when the MRL was incorporated in 2019.

Simulation was performed without fiducial marker placement because of the direct tumor visualization provided by the ViewRay MRIdian system, which obviated the need for a surrogate marker. The patients laid supine with arms at the side for patient comfort without immobilization. Simulation was performed with deep inspiration breath hold (DIBH) for 25 seconds to obtain a 3-dimensional MRI and a representative sagittal slice where the primary tumor was identified. The Siemens MRI system within the MRIdian uses the balanced steady-state free precession sequence (TrueFISP). The patient is subsequently marked at the laser sites and taken to the computed tomography (CT) simulator. The patient is then placed in an identical supine position and undergoes a DIBH CT scan with and without intravenous and oral...
Target and OAR contours were performed on the TrueFISP scan. The CT scan was deformably registered to TrueFISP scan for predictive dose calculation. The ViewRay MRIdian system uses a step-and-shoot intensity modulated RT treatment delivery technique. Intensity modulated RT plans were generated with Monte Carlo dose calculation and magnetic field corrections.

GTV and tumor vessel interface were defined as gross tumor within pancreas as seen on diagnostic imaging and simulation CT or MR scans. This volume was isotropically expanded by 3 mm to create the nominal planning target volume (PTV). The PTV was then isotropically expanded by 3 cm to create an OAR eval structure, within which OAR were recontoured daily. OAR that required contours included the stomach, duodenum, small bowel, large bowel, kidneys, liver, and spinal cord, as they are in conventional pancreatic SBRT plans (full constraints summarized in Table 1). OAR that may trigger adaptation, including the duodenum, stomach, and bowel, were combined into a single structure and expanded by 5 mm to create planning OAR volumes. This avoidance structure was then subtracted from the nominal PTV to generate a PTVopt structure that was modified during the daily adaptation process. The densWater, densAir, and densOther structures were also added before plan exportation to account for daily density changes. PTV prescriptions were 40 to 55 Gy, with lower doses used if considerable concern for toxicity was present during the treatment planning phase, such as duodenal abutment or involvement. Forty Gy was also used for the initial patients treated with our MRL when our system came online in March 2019. Daily adaptation was added to our workflow for PA in July 2019.

Before treatment delivery, the base plan was used to determine the predicted dose distribution on the anatomy of the day. The new target and OAR metrics achieved by the base plan upon the daily anatomy were then evaluated to determine whether violations occurred (Table 1). Online adaptation was triggered if there was insufficient PTV coverage or if critical OAR dose exceeded predetermined allowed limits. Real-time tracking on a sagittal scan every 250 ms was performed with automatic gating. Automatic gating parameters were set to pause treatment if the target moved ≥5% outside of the prespecified region as determined before each treatment. DIBH was used during treatment to optimize duty cycle efficiency.

After completion of 5-fraction A-SMART, patients were restaged in 4 weeks with positron emission tomography/CT scans, as well as CT scans of the chest, pelvis, and the pancreas with a specific protocol scan. Patients without evidence of disease progression continued the operable management track if that aligned with the pancreas tumor board recommendation. In rare cases, initially non-operable localized PA converted to an operable type, and they were then transitioned to an operable management workflow track within our institution. Surgical resection was typically performed between 6 to 8 weeks after RT. After appropriate surgical screening, the patients underwent surgical exploration and resection via total pancreatectomy, pancreaticoduodenectomy (aka Whipple procedure), or distal pancreatectomy based upon tumor anatomic position and geometry. Only those patients who underwent definitive surgery with curative intent were included in this study.

The resected tumor specimens were examined at the time of grossing to confirm anatomic tumor site. If there was no residual grossly visible tumor, then the residual area with fibrosis was submitted for further evaluation. All the sections derived from the tumor bed were assessed by an expert pancreatic pathologist. Tumor response was evaluated according to the College of American Pathologists tumor regression grading (CAP-TRG) criteria, ranging from CAP grade 0, indicating pathologic complete response (pCR); CAP grade 1, indicating marked response (minimal residual cancer with single cells or small groups of cancer cells); CAP grade 2, indicating moderate response.

Table 1  Dose constraints for 5 fraction A-SMART

| OAR                                    | Objective*                        |
|-----------------------------------------|-----------------------------------|
| Bowel                                   | 39.5 Gy max dose, <25 Gy mean     |
| Stomach and duodenum                    | 38 Gy max dose, <38 Gy mean       |
| Stomach, duodenum, and bowel            | V32 Gy cc ≤ 2 cc                  |
| Stomach, duodenum, and bowel            | V35 Gy cc ≤ 0.5 cc                |
| Kidneys (right and left)                | Mean < 10 Gy                      |
| Spinal cord                             | 20 Gy max dose                    |
| Critical constraints triggering online adaptation |                                  |
| Stomach, duodenum, and bowel            | Point dose max ≥ 39.5 Gy          |
| Stomach, duodenum, and bowel            | Max 0.5 cc ≥ 35 Gy                |

Abbreviations: A-SMART = ablative dose stereotactic magnetic resonance-guided adaptive radiation therapy; OAR = organs at risk.

*Hottest voxel is 10 Gy in 30% subvolume that receives the lowest overall dose.
(residual cancer outgrown by fibrosis); or CAP grade 3, indicating no response (extensive residual cancer).

Toxicity was prospectively evaluated and recorded at time of patient follow-up and according to Common Terminology Criteria for Adverse Events, version 5.0. Ordinal logistic regression model was used to assess the association between clinical factors and TRG (ie, time interval from A-SMART to surgery, receipt of chemotherapy, and RT dose). Patient OS and progression free survival (PFS) were evaluated using Kaplan-Meier analysis from time of diagnosis to most recent in-person clinical follow-up. LC was defined as absence of radiographic or clinical disease progression or recurrence within the treatment field. PFS was defined as the interval between the time of biopsy with tissue diagnosis to failure or death. Statistical analyses were performed using JMP version 16 Pro (SAS Institute Inc, Cary, NC). Follow-up included reimagining with contrast-enhanced abdominal CT or MRI scans and carbohydrate antigen 19-9 at least every 3 months.

Results

We retrospectively identified 26 patients with localized PA tumors who received A-SMART followed by surgical resection with curative intent. Patient, tumor, and treatment characteristics are summarized in Table 2. Median age at diagnosis was 68 (range, 34-86) years. Localized PA types consisted of BR (80.8%), locally advanced (LA) (11.5%), and resectable (7.7%). Most tumors were located at the head/neck of the pancreas (69%). Four patients had clinically node positive disease (16%) at time of diagnosis. Most patients received neoadjuvant chemotherapy (84.6%) before RT, with 81.8% receiving FOLFIRINOX and 18.2% receiving gemcitabine/nab-paclitaxel. Median total cycle count was 6.5 (range, 3-12) for FOLFIRINOX and 5 (range, 4-10) for gemcitabine/nab-paclitaxel. All patients received MR-guided ablative dose SBRT to a median dose of 50 (range, 40-50) Gy in 5 fractions. Median GTV of delivered plans, which is defined as the mean of appropriately weighted delivered base plan and adaptive plans, was 84.6 (range, 18.9-100) cm³. Median delivered max dose to the bowel, duodenum, and stomach of delivered plans were 34.64 (range, 16.93-39.25) Gy, 35.70 (range, 15.20-38.71) Gy, and 34.56 (range, 8.59-39.50) Gy, respectively. On-table adaptive replanning was performed in 88% of patients, with 74% having all 5 fractions adapted. The median time to resection was 50 (range, 37-115) days, and the procedure types included Whipple (69%), distal (23%), and total pancreatectomy (8%). Median intraoperative time was 7 hours and 10 minutes (range, 3:57-12:12). Most patients received adjuvant chemotherapy (61.5%), with the majority receiving FOLFIRINOX (56.3%) and the rest receiving gemcitabine/nab-paclitaxel (43.7%). The median chemotherapy cycle count was 3 (range, 1-12). Total therapy duration, including both neoadjuvant and adjuvant, was 119 (range, 14-273) days.

Clinical and pathologic outcomes and toxicities are summarized in Table 3. The majority (88.5%) of patients demonstrated moderate-to-significant treatment response (TRG grade 0-2), with 2 patients (8%) achieving pCR. Increasing time from RT was associated with lower TRG (R² = 0.22, P = .0003). In an ordinal logistic regression modeling including the time interval from A-SMART until surgery (continuous variable), the receipt of neoadjuvant chemotherapy (categorical), and RT dose (continuous), interval time from A-SMART was the only variable significantly associated with TRG, where increased time interval was associated with decreased TRG (P = .007). The vast majority (96%) of patients had an R0 resection and the median postoperative hospital stay was 7 days (4-13). All treated lymph nodes were negative at time of resection.

The median follow-up after RT was 16.5 (range, 3.9-26.2) months, during which 9 patients recurred, and 3 patients died of disease. There were no deaths associated with toxicities related to A-SMART or surgical resection. The derived median PFS from diagnosis was 13.2 months (Fig. 1A). Median OS was not reached (95% confidence interval [CI], 26.5 months — not reached). The 1- and 2-year OS rates were 100% (95% CI, 0.87-1.00) and 82% (95% CI, 0.61-0.93), respectively. The 1-year freedom from local failure rate was 96%, with the only local recurrence occurring in the patient with a R1 resection. The median PFS from diagnosis was 24 months (95% CI, 16.2 months — not reached; Fig. 1B). TRG score was significantly associated with PFS on Kaplan-Meier analysis (P = .02; Fig. 2). There were 2 patients who experienced grade 1 acute nausea and 1 patient who experienced grade 1 fatigue. There were no acute grade 2+ toxicities associated with RT in this cohort.

Between April 2019 and May 2021, our institution treated 128 patients with PA with A-SMART, and none of these patients were prevented from undergoing surgical resection because of RT-related toxicities. Patients did not proceed to surgical resection either because of medical inoperability before A-SMART or their disease not meeting resectability criteria with restaging imaging. Two patients met NCCN resectability criteria and were recommended preoperative A-SMART at multidisciplinary tumor board review because of their high risk for positive margins. No postoperative deaths occurred within 90 days. Postoperative complication rates were low, with infection/abscess formation being the most common (19%) and chyle leak (15%) being the second-most common. Hemorrhages were rare (2/26; 8%) but both were grade 4. One patient had a hematoma formation because of hemorrhage from their celiac stump that required urgent stenting 17 days after their total pancreatectomy, splenectomy, and cholecystectomy with celiac axis resection. The other patient who experienced a grade 4
hemorrhage presented to an outside hospital 18 days after their Whipple procedure with a minor hemorrhage from gastrostomy-jejunostomy tube. This was presumed to be a rectus sheath hematoma. They were subsequently started on enoxaparin as an inpatient because of their history of pulmonary embolism and cardiac thrombus formation. Their hemorrhage rapidly progressed to a grade 4 that required emergent coil embolization of left superior epigastric artery, 5 units of packed red blood cells, and an intensive care unit stay of approximately 3 days before transfer to our institution where the rest of their course was noncomplicated. One patient was hospitalized 15 days after their distal pancreatectomy because of a non-ST-elevation myocardial infarction. The patient had a 48-year smoking history with cessation in the week before their surgery in addition to poorly controlled type

| Table 2 | Patient, tumor, and treatment characteristics |
|---------|-----------------------------------------------|

| n (range/%/hh:mm) | n (range/%/hh:mm) |
|-------------------|-------------------|
| Age at diagnosis (y) | 68 (34-86) |
| Sex | |
| Female | 16 (62%) |
| Male | 10 (38%) |
| Histology | |
| Adenocarcinoma | 26 (100%) |
| Tumor location (on pancreas) | |
| Head/neck | 18 (69%) |
| Body/tail | 8 (31%) |
| Tumor cT stage | |
| 1 | 5 (19%) |
| 2 | 13 (50%) |
| 3 | 4 (15%) |
| 4 | 4 (15%) |
| Tumor cN stage | |
| 0 | 22 (85%) |
| 1 | 3 (12%) |
| 2 | 1 (4%) |
| Resectability | |
| Resectable | 2 (8%) |
| Borderline | 21 (80%) |
| Locally advanced | 3 (12%) |
| Neoadjuvant chemotherapy | |
| None | 4 (15%) |
| FOLFIRINOX | 18 (69%) |
| Gemcitabine/abraxane | 4 (15%) |
| Cycle count, median | 6 (3-12) |
| Time from last cycle to RT start (day) | 20 (5-88) |
| RT dose and fractionation | |
| Total dose, median (Gy) | 50 (40-55) |
| Number of fractions, median | 5 (5-5) |
| BED a/β = 10, median (Gy) | 100.0 (72.0-115.5) |
| BED a/β = 3, median (Gy) | 216.7 (146.7-256.7) |
| EQD210 (Gy) | 83.3 (60.0-96.2) |
| EQD23 (Gy) | 130.0 (88.0-154.0) |
| Median delivered plan RT target volumes and dose | |
| GTV, prescription (cm³) | 84.6 (18.9-100) |
| GTV D95 (cGy) | 4248.8 (3052.2-5379) |
| GTV V55 (%) | 40.3 (0-83) |
| GTV V50 (%) | 75.7 (0-100) |
| Post-RT surgery | |
| Whipple | 18 (69%) |
| Total pancreatectomy | 2 (8%) |
| Distal pancreatectomy | 6 (23%) |
| Time from RT to surgery, d | 50 (37-115) |
| Intraoperative time | 7:10 (03:57-12:12) |
| Intraoperative time, Whipple | 7:41 (05:51-12:12) |
| Intraoperative time, distal panc. | 4:26 (03:57-06:01) |
| Intraoperative time, total panc. | 10:17 |
| Adjuvant chemotherapy | |
| None | 10 (38%) |
| FOLFIRINOX | 9 (35%) |
| Gemcitabine/abraxane | 7 (27%) |
| Cycle count, median | 3 (1-12) |
| Cycle count, total (neo + adjuvant) | 8.5 (1-18) |

Abbreviations: BED = biologically effective dose; cN = clinical nodal stage; cT = clinical tumor stage; EQD2 = equivalent dose in 2 Gy per fraction; FOLFIRINOX = Leucovorin Calcium (Folinic Acid), Fluorouracil, Irinotecan Hydrochloride, and Oxaliplatin; GTV = gross tumor volume; panc = radiation therapy.

(continued on next page)
2 diabetes mellitus. The last patient was hospitalized 9 days after their Whipple procedure because of a grade 2 chyle leak that resolved with diet modification. They stayed overnight for observation and were discharged in the morning. There were no fistulae formation toxicities observed. In total, 4 patients were hospitalized within 90 days and all patients survived to discharge. An additional 4 other patients were hospitalized through the entire follow-up time, but none of these hospitalizations were related to surgical or RT toxicity. There are no known deaths related to either A-SMART or surgical resection within the entire follow-up time.

### Discussion

In this study, we explored the feasibility and safety of A-SMART followed by surgical resection of PA and demonstrated low rates of toxicity from RT as well as favorable surgical and oncological results. The overall added Table 3  RT toxicities, surgical outcomes, and pathologic outcomes

| RT toxicity                                | n (range/%)                      |
|--------------------------------------------|----------------------------------|
| Acute, grade 1                            | 3 (12%; 2 nausea, 1 fatigue)    |
| Acute, grade 2+                           | 0                                |
| Late, grade 1+                            | 0                                |
| Surgical mortality, within 90 d           | 0                                |
| Postsurgical complications, within 90 d   |                                  |
| Pancreatic anastomosis leak, grade 1      | 2 (8%)                           |
| Chyle leak, grade 1                       | 2 (8%)                           |
| Chyle leak, grade 2                       | 2 (8%)                           |
| Delayed gastric emptying, grade 2         | 1 (4%)                           |
| Postoperative wound infection, grade 2    | 2 (8%)                           |
| Postoperative wound infection, grade 3    | 1 (4%)                           |
| Retroperitoneal abscess, grade 3          | 1 (4%)                           |
| Hemorrhage, grade 4                       | 2 (8%)                           |
| Fistulae                                  | 0                                |

| Length of hospitalization, d              | 8 (4-13)                         |
| Rehospitalization, within 90 d           | 4 (15%)                          |

| CAP-TRG                                   |                                  |
|-------------------------------------------|----------------------------------|
| 0                                         | 2 (8%)                           |
| 1                                         | 6 (23%)                          |
| 2                                         | 15 (58%)                         |
| 3                                         | 3 (12%)                          |

| Resection status                          |                                  |
|-------------------------------------------|----------------------------------|
| R0                                        | 25 (96%)                         |
| R1                                        | 1 (4%)                           |

| Postsurgical hospitalization length, median (d) | 7 (4-13) |
|------------------------------------------------|----------|

| OS, median (mo) | Not reached (95% CI, 26.5 months − infinity) |
|-----------------|-----------------------------------------------|
| OS, 1 y         | 100%                                          |
| OS, 2 y         | 82%                                           |
| PFS, median (months) | 24 (95% CI, 16.2 months − infinity)      |
| FFLF, 1 y       | 96%                                           |

**Abbreviations:** CAP-TRG = College of American Pathologists tumor regression grading; CI = confidence interval; FFLF = freedom from local failure; OS = overall survival; PFS = progression free survival; RT = radiation therapy.
surgical complexity was low, evidenced by low rates of surgical complications and high rates of margin negative resection (96%) despite a high proportion of initially BR and LA patients (92%). Eighty-eight percent of patients demonstrated a pathologic response (TRG 0-2). This regimen afforded impressive LC, with only 1 local failure at 12 months (1-year freedom from local failure 96%) in the patient who had an R1 resection. This robust LC facilitated long-term disease control with an excellent 1-year OS of 100% and PFS of 24 months (95% CI, 16.2 months – not reached). Importantly, toxicity related to A-SMART has not prevented any patients treated at our institution from proceeding to surgical resection. These results may offer an opportunity for further investigation into ablative preoperative treatment for localized PA.

R0 resection remains the best path to potential cure for localized PA. However, with a surgery-first approach, up to 50% of patients will develop a local recurrence.11,12

Figure 1  (A) Kaplan-Meier plot of patient survival measured from time of diagnosis. Median overall survival (OS) was not reached (95% confidence interval [CI], 26.5 months – not reached). (B) Kaplan-Meier plot of progression free survival (PFS) measured from time of diagnosis. Median PFS was 24 months (95% CI, 16.2 months – not reached).

Figure 2  Kaplan-Meier plot of time from diagnosis to clinically relevant outcomes stratified by tumor regression grading (TRG). Clinically relevant outcomes of death and disease progression are inversely correlated with TRG ($P = .02$). Paradoxical improved clinical outcome of TRG 3 most likely due to limited number of patients with this pathologic event (n = 3).
In approximately 25% of these patients, local disease recurrence is the sole site of disease progression. Preoperative therapy allows for biological selection of patients for curative resection, and despite the oncological benefits of preoperative therapy for localized PA, only 50% of BR and 10% of LA patients undergo successful resection after undergoing neoadjuvant chemotherapy.

Preoperative SBRT helps to sterilize surgical margins to improve R0 resection rates, leading to improved LC for resected patients. However, a significant portion of patients with BR or LA disease will never make it to resection, and an ablative dose may improve LC for these patients.

The R0 resection rates within this experience and other retrospective A-SMART cohorts are comparable to prior preoperative SBRT for localized PA studies. Zakem et al. reported a negative margin rate of 97% for patients who underwent surgery after SBRT of 30 to 33 Gy. Bouchart et al. reported on 19 patients treated with CT-based ablative dose SBRT that resulted in R0 rates congruent with lower dose SBRT historical cohorts and 18-month OS rate of 87%. Almost all patients within this cohort experienced grade 1 to 2 acute toxicities, and the acute grade 3 toxicity rate approached 10%. A-SMART appears to be better tolerated compared with CT-based ablative dose SBRT, as historical cohorts experienced far higher grade 1 to 3 RT-related acute toxicities, ranging from 50% to 100%, compared with only 12% of patients within our cohort. Although these acute toxicities did not appear to have prevented surgical resection, decreased patient morbidity appears to be facilitated by adaptive treatment.

Isoxic dose-escalation may be best facilitated through MRgRT, offering a unique advantage over previous pancreatic SBRT techniques because of the superior soft tissue visualization of MR and an ability to monitor inter- and intrafraction OAR position and movement. Rudra et al. reported a series of 44 patients who were treated with MRgRT by conventionally fractionated, hypofractionated, or SBRT approaches for their localized PA. Upon stratified analysis of standard (BED10 ≤ 70 Gy) versus ablative (BED10 > 70 Gy) dose, significant improvements of clinical outcomes, including higher OS and lower grade 3 gastrointestinal toxicity, were associated with ablative dose MRgRT. Previously, there have been limited descriptions of patients undergoing successful tumor resection after A-SMART in other retrospective experiences. Hassanzadeh et al. reported on a series of 44 patients treated with A-SMART, and reported on 4 patients able to proceed to surgery, with 3 patients undergoing tumor resection with 1 patient with a positive margin; however, 1 surgery was aborted because of excessive fibrosis. Finally, Chuong et al. reported a series of 35 patients treated with 5-fraction A-SMART on an MR linear accelerator with localized and unresectable PA and demonstrated a very favorable toxicity profile with no acute or late grade 4 or 5 toxicities and less than 3% acute and late grade 3 toxicities. The 1-year LC and OS rates were 87.8% and 58.9%, respectively. In this experience, 5 patients (60% BR) underwent a Whipple procedure performed at a median of 2 (range, 1-9) months after completion of A-SMART to median radiation dose of 50 Gy. All resected patients received induction FOLFIRINOX (n = 4) or gemcitabine/nab-paclitaxel (n = 1). Four patients were successfully resected with negative margins, 1 patient experienced a complete response (TRG 0), and 2 patients had a near complete pathologic response (TRG 1). None of the resected patients had evidence of tumor recurrence after median 10.8 months follow-up.

Despite these results, there is hesitation with preoperative ablative dose SBRT due to concerns of increased surgical morbidity and mortality secondary to increased degree of local fibrosis associated with higher RT dose. Within 90-days postoperatively, in our experience there was no mortality, and only 4 patients (15%) were readmitted. These outcomes compare favorably with historical open and robot-assisted Whipple surgery rates, with postoperative 90-day mortality ranging from 2% to 3% and rehospitalization rates from 23% to 31%. Furthermore, the median hospitalization of 8 days (range, 4-13) within our cohort is comparable to post-Whipple hospitalization stays that can range from 4 days to as high as 5 months.

In comparison to conventional SBRT experiences, grade 4 postsurgical complication rates have been reported as high as 21% compared with 8% within our A-SMART cohort.

Lastly, a notable finding in this study is the positive correlation between time interval between RT and improvement in pathologic outcomes (P = .0003). To the best of our knowledge, this is the first reported analysis of time interval from RT to pathologic outcome in PA. Increasing time interval between RT and improved pathologic response has been reported for other gastrointestinal sites. Data from rectal cancer in the Timing of Rectal Cancer Response to Chemoradiotherapy Trial demonstrated that longer neoadjuvant chemotherapy durations after chemoradiation were associated with improved pCR rates of up to 38%. The mechanism for this continuing effect of RT after SBRT may be secondary to fibrosis of local vasculature that reduces nutrient supply to the tumor and an in vivo immunization to the localized tumor antigens produced with ablative doses. Our study was not powered to assess the effect of type or duration of chemotheraphy; however, time from RT was the only statistically significant predictor for improved pathologic outcomes compared with neoadjuvant chemotherapy and total radiation therapy dose. Our data confirm previously published reports demonstrating an association of PFS with TRG. As data mount in support of neoadjuvant therapy for PA, we await
prospective validation of TRG as a surrogate endpoint of clinical significance.

Limitations of our study include its retrospective design, making it subject to underreporting of toxicities, although these were prospectively recorded at time of follow-up. We have multiple pancreatic cancer pathologists at our institution and thus could not control for interpersonal pathologic evaluation bias. There is a significant variance of neoadjuvant and adjuvant chemotherapy in both regimen type and total cycles, and thus the effect of chemotherapy on clinical outcomes in this cohort was unable to be assessed. The cohort consisted of BR, LA, and resectable patients, according to NCCN definitions, contributing to overall patient heterogeneity. There was a relatively short follow-up because of the recent implementation of this A-SMART regimen. There was no comparator arm of patients treated with standard-dose CT-based SBRT. Lastly, it should be noted that there may be limited generalizability of these results because of the nature of our experience as a high-volume institution.

Looking forward, we await the results of the Stereotactic MRI-Guided On-Table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer trial (NCT03621644), which is the first prospective trial to evaluate A-SMART in BR and LA PA. In this trial, they are delivering 50 Gy in 5 fractions to these lesions to evaluate A-SMART in BR and LA PA. In this trial, they (NCT03621644), which is the SMART for Locally Advanced Pancreatic Cancer trial.

Conclusions

PA resection after A-SMART appears to be safe and well tolerated without preoperative grade 2+ morbidity, postoperative grade 3 to 4 toxicity rates of 8%, and no 90-day postsurgical mortality. No patients with localized PA and treated with A-SMART at our institution were prevented from undergoing surgical resection because of A-SMART–associated toxicity. Results from prospective studies using A-SMART in combined modality therapy against PA are eagerly awaited and may potentially validate our novel findings, suggesting that the time from SBRT to surgical resection is associated with pathologic response.

Acknowledgments

Funding support from ViewRay, Inc.

References

1. Howlader N NA, Krapcho M, Miller D, et al. SEER Cancer Statistics Review, 1975–2017. Bethesda, MD: National Cancer Institute; 2020.
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
3. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–387.
4. Zovak M, Muzina Míšic D, Glavic G. Pancreatic surgery: Evolution and current tailored approach. Hepatobiliary Surg Nutr. 2014;3: 247–258.
5. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology, J Natl Compr Canc Netw. 2021;19:439–457.
6. O’Reilly D, Fou L, Hasler E, et al. Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence. Pancreatology. 2018;18:962–970.
7. Conroy T, Hammel P, Hebbel M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–2406.
8. Muggio M, Malleo G, Marchegiani G, et al. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg. 2019;154:932–942.
9. Groot VP, Rezaee N, Wu W, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267:936–945.
10. Strobel O, Hank T, Hinz U, et al. Pancreatic cancer surgery: The new R-status counts. Ann Surg. 2017;265:565–573.
11. Asiyanbola B, Gleisner A, Herman JM, et al. Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-fluorouracil-based chemoradiation therapy: Effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg. 2009;13:752–759.
12. Ghanem P, Kleeff J, Halloran CM, et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg. 2019;269:520–529.
13. Kharofa J, Tsai S, Kelly T, et al. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. Radiother Oncol. 2014;113:41–46.
14. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: The importance of this emerging stage of disease. J Am Coll Surg. 2008;206:833–846. discussion 846-848.
15. Mellon EA, Hoffe SE, Springitt GM, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015;54:979–985.
16. Ujiri T, Teshima T, Mochizuki Y, et al. Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: An analysis for the impact of radiation and gemcitabine doses. Radiother Oncol. 2015;114:122–127.
17. Versteijne E, van Dam J, Luijten M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: Long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40:1220–1230.
18. Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: A prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268:215–222.
19. Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: The A012501 phase 2 randomized clinical trial [e-pub ahead of print]. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2022.2319, accessed July 17, 2022.
20. Bernard V, Herman JM. Pancreas SBRT: Who, what, when, where, and how. *Pract Radiat Oncol*. 2020;10:183–185.

21. Arcelli A, Guido A, Buwenge M, et al. Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: A multicentric analysis (PAULA-1). *Anticancer Res*. 2020;40:465–472.

22. Rudra S, Jiang N, Rosenberg SA, et al. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. *Cancer Med*. 2019;8:2123–2132.

23. Krishnan S, Chadha AS, Suh Y, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. *Int J Radiat Oncol Biol Phys*. 2016;94:755–765.

24. Ma SJ, Prezzano KM, Hermann GM, Singh AK. Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer. *Radiother Oncol*. 2018;13:214.

25. Chuong MD, Bryant J, Mittauer KE, et al. Ablative 5-fraction stereotactic magnetic resonance-guided radiation therapy with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer. *Praec Radiat Oncol*. 2021;11:134–147.

26. Tchelebi LT, Zaorsky NG, Rosenberg JC, et al. Reducing the toxicity of radiotherapy for pancreatic cancer with magnetic resonance-guided radiotherapy. *Toxicol Sci*. 2020;175:19–23.

27. Bohoudi O, Bruynzeel AME, Senan S, et al. Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer. *Radiother Oncol*. 2017;125:439–444.

28. Boldrini L, Cusumano D, Cellini F, Azario L, Mattiucci GC, Valentini V. Online adaptive magnetic resonance guided radiotherapy for pancreatic cancer: State of the art, pearls and pitfalls. *Radiat Oncol*. 2019;14:71.

29. Chen-Zhao X, Hernandez O, Lopez M, et al. A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy (SBRT) as a neoadjuvant strategy of chemoradiation in pancreatic cancer. *Clin Transl Oncol*. 2020;22:1499–1505.

30. Hill C, Sehgal S, Fu W, et al. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy. *Cancer Med*. 2022;11:1659–1668.

31. Zakem SJ, Mueller AC, Meguid C, et al. Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer. *HPB (Oxford)*. 2021;23:1072–1083.

32. Bouchart C, Engelholm JL, Closet J, et al. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma. *Ther Adv Med Oncol*. 2021;13:17588359211045860.

33. Reynold M, O’Reilly EM, Varghese AM, et al. Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer. *JAMA Oncol*. 2021;7:735–738.

34. Hassanzadeh C, Rudra S, Bommireddy A, et al. Ablative five-fraction stereotactic body radiation therapy for inoperable pancreatic cancer using online MR-guided adaptation. *Adv Radiat Oncol*. 2021;6:100506.

35. Henke L, Kashani R, Yang D, et al. Simulated online adaptive magnetic resonance-guided stereotactic body radiation therapy for the treatment of oligometastatic disease of the abdomen and central thorax: Characterization of potential advantages. *Int J Radiat Oncol Biol Phys*. 2016;96:1078–1086.

36. Henke L, Kashani R, Robinson C, et al. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. *Radiother Oncol*. 2018;126:519–526.

37. Zureikat AH, Postliewait LM, Liu Y, et al. A multi-institutional comparison of perioperative outcomes of robotic and open pancreaticoduodenectomy. *Ann Surg*. 2016;264:640–649.

38. Mellon EA, Strom TJ, Hofie SE, et al. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer. *J Gastrointest Oncol*. 2016;7:547–555.

39. Ryan R, Gibbons D, Hyland JM, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. *Histopathology*. 2005;47:141–146.

40. Haisley KR, Laird AE, Nabavizadeh N, et al. Association of intervals between neoadjuvant chemoradiation and surgical resection with pathologic complete response and survival in patients with esophageal cancer. *JAMA Surg*. 2016;151:e162743.

41. Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: A multicentre, phase 2 trial. *Lancet Oncol*. 2015;16:957–966.

42. Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRS and SBRT: Are more than the 5 Rs involved? *Int J Radiat Oncol Biol Phys*. 2014;88:254–262.

43. Mellon EA, Jin WH, Frakes JM, et al. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. *Acta Oncol*. 2017;56:391–397.

44. Hoffe SE, Frakes JM, Aguiler TA, et al. Randomized, double-blinded, placebo-controlled multicenter adaptive phase 1-2 trial of GC 4419, a dismutase mimetic, in combination with high dose stereotactic body radiation therapy (SBRT) in locally advanced pancreatic cancer (PC). *Int J Radiat Oncol Biol Phys*. 2020;108:1399–1400.

45. Hoffe SE, Malafa M, Costello J, et al. GRECO-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with GC4711 in the treatment of unresectable or borderline resectable nonmetastatic pancreatic cancer (PC). *ASTRO 63rd Annual Meeting*. Int J Radiat Oncol Biol Phys. 2021:e44–e45.